Selinexor-based regimens in patients with multiple myeloma after prior anti-B-cell maturation antigen treatment

eJHaem

article

Muhamed Baljevic¹  Cristina Gasparetto²  Gary J. Schiller³  Sascha A. Tuchman⁴  Natalie S. Callander⁵  Suzanne Lentzsch⁶  Jorge Monge⁷  Rami Kotb⁸  Nizar J. Bahlis⁹  Darrell White^1,10  Christine I. Chen^1,11  Heather J. Sutherland^1,12  Sumit Madan^1,13  Richard LeBlanc^1,14  Michael Sebag^1,15  Christopher P. Venner^1,16  William I. Bensinger^1,17  Noa Biran^1,18  Andrew DeCastro^1,19  Dane R. Van Domelen^1,19  Chris Zhang^1,19  Jatin J. Shah^1,19  Sharon Shacham^1,19  Michael G. Kauffman^1,19  Ohad S. Bentur^1,19  Brea Lipe^2,20 

[1] Vanderbilt-Ingram Cancer Center, Vanderbilt University Medical Center;Duke Cancer Institute, Duke University;Hematological Malignancy/Stem Cell Transplant Program, University of California - Los Angeles David Geffen School of Medicine;Department of Medicine, Division of Hematology, The University of North Carolina at Chapel Hill;Division of Hematology/Oncology, Department of Medicine, University of Wisconsin-Madison School of Medicine and Public Health;Columbia University Medical Center;Weill Cornell Medicine;Medical Oncology and Hematology CancerCare Manitoba;Arnie Charbonneau Cancer Research Institute, University of Calgary;Department of Medicine/Division of Hematology, Dalhousie University;Princess Margaret Cancer Centre;Division of Hematology, Vancouver General Hospital;Banner MD Anderson Cancer Center;Maisonneuve-Rosemont Hospital, University of Montreal;Division of Hematology, McGill University Health Centre;Cross Cancer Institute, University of Alberta;Center for Blood Disorders and Stem Cell Transplantation Swedish Cancer Institute;John Theurer Cancer Center, Hackensack Meridian Health, Hackensack University Medical Center;Karyopharm Therapeutics Inc.;Wilmot Cancer Institute, University of Rochester Medical Center

关键词: anti-BCMA;    multiple myeloma;    selinexor;   

DOI  :  10.1002/jha2.572

来源: Wiley

【 摘 要 】

There is a lack of consensus on therapy sequencing in previously treated multiple myeloma, particularly after anti-B-cell maturation antigen (BCMA) therapy. Earlier reports on selinexor (X) regimens demonstrated considerable efficacy in early treatment, and after anti-BCMA-targeted chimeric antigen receptor-T cell therapy. Here, we present data from 11 heavily pretreated patients who predominantly received BCMA-antibody-drug conjugate therapy. We observe that X-containing regimens are potent and achieve durable responses with numerically higher overall response and clinical benefit rates, as well as median progression free survival compared to patients’ prior anti-BCMA therapies, despite being used later in the treatment course. In an area of evolving unmet need, these data reaffirm the efficacy of X-based regimens following broader anti-BCMA therapy.

【 授权许可】

Unknown